{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:26:38Z","timestamp":1780554398206,"version":"3.54.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Epilepsy Research Fund"},{"DOI":"10.13039\/100008052","name":"Fundaci\u00f3n Alfonso Mart\u00edn Escudero","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.seizure.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T13:19:05Z","timestamp":1533647945000},"page":"79-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Novel drugs and early polypharmacotherapy in status epilepticus"],"prefix":"10.1016","volume":"68","author":[{"given":"Marta","family":"Amengual-Gual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"S\u00e1nchez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-7462","authenticated-orcid":false,"given":"Mark S.","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1528-1167.2009.02323.x","article-title":"Refractory status epilepticus: a prospective observational study","volume":"51","author":"Novy","year":"2010","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2018.08.004_bib0015","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1474-4422(11)70187-9","article-title":"Management of refractory status epilepticus in adults: still more questions than answers","volume":"10","author":"Rossetti","year":"2011","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.seizure.2013.10.004","article-title":"Gaps and opportunities in refractory status epilepticus research in children: a multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG)","volume":"23","author":"S\u00e1nchez Fern\u00e1ndez","year":"2014","journal-title":"Seizure"},{"issue":"Pt. 10","key":"10.1016\/j.seizure.2018.08.004_bib0025","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","article-title":"The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol","volume":"134","author":"Shorvon","year":"2011","journal-title":"Brain"},{"issue":"23","key":"10.1016\/j.seizure.2018.08.004_bib0030","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1523\/JNEUROSCI.0900-05.2005","article-title":"Status epilepticus increases the intracellular accumulation of GABAA receptors","volume":"25","author":"Goodkin","year":"2005","journal-title":"J Neurosci"},{"issue":"34","key":"10.1016\/j.seizure.2018.08.004_bib0035","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1523\/JNEUROSCI.4944-04.2005","article-title":"Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus","volume":"25","author":"Naylor","year":"2005","journal-title":"J Neurosci"},{"issue":"Suppl. 12","key":"10.1016\/j.seizure.2018.08.004_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2009.02375.x","article-title":"Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited","volume":"50","author":"Wasterlain","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.nbd.2012.12.015","article-title":"Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus","volume":"54","author":"Naylor","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"Suppl. 9","key":"10.1016\/j.seizure.2018.08.004_bib0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2008.01928.x","article-title":"Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs","volume":"49","author":"Wasterlain","year":"2008","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/nyas.13147","article-title":"Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment","volume":"1378","author":"Niquet","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl. 3","key":"10.1016\/j.seizure.2018.08.004_bib0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1528-1167.2010.02622.x","article-title":"Glutamate and GABA in the balance: convergent pathways sustain seizures during status epilepticus","volume":"51","author":"Naylor","year":"2010","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.410340511","article-title":"Developmental changes in human gamma-aminobutyric acidA receptor subunit composition","volume":"34","author":"Brooks-Kayal","year":"1993","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.21167","article-title":"Neonatal seizures","volume":"62","author":"Silverstein","year":"2007","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cne.10314","article-title":"Temporal and regional expression of NMDA receptor subunit NR3A in the mammalian brain","volume":"450","author":"Wong","year":"2002","journal-title":"J Comp Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0896-6273(92)90120-3","article-title":"Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit","volume":"8","author":"Burnashev","year":"1992","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.seizure.2018.08.004_bib0085","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1523\/JNEUROSCI.22-08-03005.2002","article-title":"A developmental switch of AMPA receptor subunits in neocortical pyramidal neurons","volume":"22","author":"Kumar","year":"2002","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0090","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1528-1157.2001.12000.x","article-title":"Maturational aspects of epilepsy mechanisms and consequences for the immature brain","volume":"42","author":"Sanchez","year":"2001","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2018.08.004_bib0095","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/2661","article-title":"Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy","volume":"4","author":"Brooks-Kayal","year":"1998","journal-title":"Nat Med"},{"issue":"1-2","key":"10.1016\/j.seizure.2018.08.004_bib0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000096221","article-title":"Recurrent seizures and the molecular maturation of hippocampal and neocortical glutamatergic synapses","volume":"29","author":"Swann","year":"2007","journal-title":"Dev Neurosci"},{"issue":"7","key":"10.1016\/j.seizure.2018.08.004_bib0105","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/WNL.56.7.906","article-title":"Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia","volume":"56","author":"Crino","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.jnen.0000235117.67558.6d","article-title":"NMDA receptor composition differs among anatomically diverse malformations of cortical development","volume":"65","author":"Finardi","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.eplepsyres.2014.01.015","article-title":"Subunit composition of glutamate and gamma-aminobutyric acid receptors in status epilepticus","volume":"108","author":"Loddenkemper","year":"2014","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ana.21342","article-title":"Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers","volume":"63","author":"Talos","year":"2008","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ana.22696","article-title":"Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia","volume":"71","author":"Talos","year":"2012","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.seizure.2018.08.004_bib0130","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/nm1301","article-title":"NKCC1 transporter facilitates seizures in the developing brain","volume":"11","author":"Dzhala","year":"2005","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.seizure.2018.08.004_bib0135","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneurol.2009.80","article-title":"Epileptogenesis in the immature brain: emerging mechanisms","volume":"5","author":"Rakhade","year":"2009","journal-title":"Nat Rev Neurol"},{"issue":"32","key":"10.1016\/j.seizure.2018.08.004_bib0140","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1523\/JNEUROSCI.1734-08.2008","article-title":"Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures","volume":"28","author":"Rakhade","year":"2008","journal-title":"J Neurosci"},{"issue":"Pt. 2","key":"10.1016\/j.seizure.2018.08.004_bib0145","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/brain\/awl318","article-title":"Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy","volume":"130","author":"van Vliet","year":"2007","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0150","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1208\/s12248-017-0096-2","article-title":"Breaking bad: the structure and function of the blood-brain barrier in epilepsy","volume":"19","author":"Han","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.seizure.2018.08.004_bib0155","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0079-6123(01)32088-5","article-title":"Glial cell responses to lipids bound to albumin in serum and plasma","volume":"132","author":"Nadal","year":"2001","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.seizure.2018.08.004_bib0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.brainres.2009.11.063","article-title":"Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways","volume":"1313","author":"Ralay Ranaivo","year":"2010","journal-title":"Brain Res"},{"issue":"28","key":"10.1016\/j.seizure.2018.08.004_bib0165","doi-asserted-by":"crossref","first-page":"8927","DOI":"10.1523\/JNEUROSCI.0430-09.2009","article-title":"Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis","volume":"29","author":"Cacheaux","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.seizure.2018.08.004_bib0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2012.04.004","article-title":"The role of inflammation in epileptogenesis","volume":"69","author":"Vezzani","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.seizure.2018.08.004_bib0175","article-title":"Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies","author":"van Vliet","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tips.2016.03.001","article-title":"Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside","volume":"37","author":"Dey","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eplepsyres.2008.07.007","article-title":"Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus","volume":"82","author":"Bankstahl","year":"2008","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0190","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1517\/14656566.2015.997212","article-title":"Therapeutic choices in convulsive status epilepticus","volume":"16","author":"S\u00e1nchez Fern\u00e1ndez","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/WCO.0000000000000307","article-title":"Recent advances in status epilepticus","volume":"29","author":"Trinka","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0200","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11940-011-0148-3","article-title":"Treatment of pediatric status epilepticus","volume":"13","author":"Loddenkemper","year":"2011","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0205","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1528-1167.2006.00973.x","article-title":"Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam","volume":"48","author":"Carunchio","year":"2007","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2018.08.004_bib0210","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/j.1476-5381.2009.00463.x","article-title":"Levetiracetam inhibits glutamate transmission through presynaptic P\/Q-type calcium channels on the granule cells of the dentate gyrus","volume":"158","author":"Lee","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-444-53630-3.00008-7","article-title":"Neurosteroids: endogenous role in the human brain and therapeutic potentials","volume":"186","author":"Reddy","year":"2010","journal-title":"Prog Brain Res"},{"issue":"1-2","key":"10.1016\/j.seizure.2018.08.004_bib0220","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jnr.23853","article-title":"Sex differences in the anticonvulsant activity of neurosteroids","volume":"95","author":"Samba Reddy","year":"2017","journal-title":"J Neurosci Res"},{"issue":"7","key":"10.1016\/j.seizure.2018.08.004_bib0225","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tips.2016.04.003","article-title":"Clinical potential of neurosteroids for CNS disorders","volume":"37","author":"Reddy","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"Pt. B","key":"10.1016\/j.seizure.2018.08.004_bib0230","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.nbd.2014.06.010","article-title":"Neurosteroids and their role in sex-specific epilepsies","volume":"72","author":"Reddy","year":"2014","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0074-7742(08)00002-0","article-title":"Epidemiology and classification of epilepsy: gender comparisons","volume":"83","author":"McHugh","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0074-7742(08)00003-2","article-title":"Hormonal influences on seizures: basic neurobiology","volume":"83","author":"Frye","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0250","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.seizure.2015.02.024","article-title":"Catamenial epilepsy: update on prevalence, pathophysiology and treatment from the findings of the NIH Progesterone Treatment Trial","volume":"28","author":"Herzog","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.08.004_bib0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fncel.2013.00115","article-title":"Role of hormones and neurosteroids in epileptogenesis","volume":"7","author":"Reddy","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.seizure.2018.08.004_bib0260","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuropharm.2017.04.020","article-title":"Allopregnanolone decreases interictal spiking and fast ripples in an animal model of mesial temporal lobe epilepsy","volume":"121","author":"L\u00e9vesque","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.seizure.2018.08.004_bib0265","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.lfs.2015.09.008","article-title":"On the anticonvulsant effect of allopregnanolone (a neurosteroid) in neonatal rats","volume":"143","author":"Dhir","year":"2015","journal-title":"Life Sci"},{"issue":"Suppl. 6","key":"10.1016\/j.seizure.2018.08.004_bib0270","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/epi.12289","article-title":"Neuroactive steroids for the treatment of status epilepticus","volume":"54","author":"Rogawski","year":"2013","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2018.08.004_bib0275","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0028-3908(96)00021-4","article-title":"Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice","volume":"35","author":"Kokate","year":"1996","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0280","first-page":"411","article-title":"Effects of neurosteroids on kainate-induced seizures, neurotoxicity and lethality in mice","volume":"49","author":"Le\u015bkiewicz","year":"1997","journal-title":"Pol J Pharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0306-4530(99)00068-2","article-title":"Anti-seizure effects of progesterone and 3alpha,5alpha-THP in kainic acid and perforant pathway models of epilepsy","volume":"25","author":"Frye","year":"2000","journal-title":"Psychoneuroendocrinology"},{"issue":"1-2","key":"10.1016\/j.seizure.2018.08.004_bib0290","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0006-8993(95)00793-P","article-title":"The neurosteroid 3 alpha, 5 apha-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy","volume":"696","author":"Frye","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.seizure.2018.08.004_bib0295","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.yebeh.2016.12.024","article-title":"The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication","volume":"68","author":"Althaus","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.08.004_bib0300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nbd.2015.03.020","article-title":"Neurosteroidal modulation of in vitro epileptiform activity is enhanced in pilocarpine-treated epileptic rats","volume":"78","author":"Shiri","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neulet.2006.10.023","article-title":"The anticonvulsant effects of allopregnanolone against amygdala-kindled seizures in female rats","volume":"411","author":"Lonsdale","year":"2007","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0310","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/ana.24295","article-title":"Pediatric super-refractory status epilepticus treated with allopregnanolone","volume":"76","author":"Broomall","year":"2014","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0315","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/acn3.408","article-title":"First-in-man allopregnanolone use in super-refractory status epilepticus","volume":"4","author":"Vaitkevicius","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"issue":"Suppl. 6","key":"10.1016\/j.seizure.2018.08.004_bib0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/epi.12286","article-title":"SGE-102: a novel therapy for refractory status epilepticus","volume":"54","author":"Reddy","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0325","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ana.25008","article-title":"Brexanolone as adjunctive therapy in super-refractory status epilepticus","volume":"82","author":"Rosenthal","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0330","series-title":"SAGE Therapeutics reports top-line results from phase 3 STATUS trial of brexanolone in super-refractory status epilepticus","year":"2018"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0335","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/epi.13625","article-title":"Decreased allopregnanolone levels in cerebrospinal fluid obtained during status epilepticus","volume":"58","author":"Meletti","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0340","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nurt.2006.11.003","volume":"4","author":"Nohria","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0345","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.13705","article-title":"Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures","volume":"58","author":"Sperling","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0350","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fncel.2017.00246","article-title":"Ganaxolone: a new treatment for neonatal seizures","volume":"11","author":"Yawno","year":"2017","journal-title":"Front Cell Neurosci"},{"issue":"Suppl. 3","key":"10.1016\/j.seizure.2018.08.004_bib0355","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1528-1167.2010.02629.x","article-title":"Females, their estrogens, and seizures","volume":"51","author":"Vel\u00edskov\u00e1","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0360","first-page":"5","article-title":"Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model","author":"Sato","year":"2016","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0365","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.maturitas.2008.10.014","article-title":"Estrogen effects on pilocarpine-induced temporal lobe epilepsy in rats","volume":"62","author":"Pereira","year":"2009","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0370","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14737175.2017.1288099","article-title":"Ketamine for the treatment of (super) refractory status epilepticus? Not quite yet","volume":"17","author":"Dorandeu","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0375","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cns.12096","article-title":"Treatment of status epilepticus with ketamine, are we there yet?","volume":"19","author":"Dorandeu","year":"2013","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0380","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(99)00238-4","article-title":"N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat","volume":"265","author":"Mazarati","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.seizure.2018.08.004_bib0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2018.04.029","article-title":"Non-anesthetic effects of ketamine, a review article Authors","author":"Eldufani","year":"2018","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0390","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0395","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12028-013-9939-6","article-title":"NMDA antagonists for refractory seizures","volume":"20","author":"Zeiler","year":"2014","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.seizure.2018.08.004_bib0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.seizure.2015.05.010","article-title":"Ketamine for the treatment of refractory status epilepticus","volume":"30","author":"Fang","year":"2015","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0405","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40263-016-0371-2","article-title":"(S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study","volume":"30","author":"H\u00f6fler","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2018.08.004_bib0410","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.yebeh.2015.06.019","article-title":"Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation","volume":"49","author":"Ilvento","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0415","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/0972-5229.156484","article-title":"Intravenous ketamine for treatment of super-refractory convulsive status epilepticus with septic shock: a report of two cases","volume":"19","author":"Shrestha","year":"2015","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0420","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pediatrneurol.2014.03.006","article-title":"Use of ketamine in a newborn with refractory status epilepticus: a case report","volume":"51","author":"Tarocco","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"1-2","key":"10.1016\/j.seizure.2018.08.004_bib0425","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eplepsyres.2013.01.007","article-title":"Ketamine use in the treatment of refractory status epilepticus","volume":"105","author":"Synowiec","year":"2013","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.seizure.2018.08.004_bib0430","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/epi.12247","article-title":"Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study","volume":"54","author":"Gaspard","year":"2013","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.seizure.2018.08.004_bib0435","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/1060028013505427","article-title":"Ketamine continuous infusion for refractory status epilepticus in a patient with anticonvulsant hypersensitivity syndrome","volume":"47","author":"Esaian","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"24","key":"10.1016\/j.seizure.2018.08.004_bib0440","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1212\/WNL.0b013e318278b685","article-title":"Efficacy and safety of ketamine in refractory status epilepticus in children","volume":"79","author":"Rosati","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0445","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e3181d1e3cd","article-title":"Terminating prolonged refractory status epilepticus using ketamine","volume":"33","author":"Hsieh","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"2-3","key":"10.1016\/j.seizure.2018.08.004_bib0450","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.eplepsyres.2008.08.005","article-title":"Ketamine successfully terminates malignant status epilepticus","volume":"82","author":"Pr\u00fcss","year":"2008","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2018.08.004_bib0455","article-title":"Early use of the NMDA receptor antagonist ketamine in refractory and superrefractory status epilepticus","author":"Zeiler","year":"2015","journal-title":"Crit Care Res Pract"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0460","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12028-013-9858-6","article-title":"Ketamine for medically refractory status epilepticus after elective aneurysm clipping","volume":"19","author":"Zeiler","year":"2013","journal-title":"Neurocrit Care"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0465","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1212\/WNL.51.6.1765","article-title":"Refractory status epilepticus: response to ketamine","volume":"51","author":"Sheth","year":"1998","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.seizure.2018.08.004_bib0470","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0883073817698629","article-title":"Increasing ketamine use for refractory status epilepticus in US pediatric hospitals","volume":"32","author":"Keros","year":"2017","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0475","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annemergmed.2014.06.018","article-title":"The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review","volume":"65","author":"Cohen","year":"2015","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0480","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.annemergmed.2014.08.025","article-title":"Ketamine and intracranial pressure: no contraindication except hydrocephalus","volume":"65","author":"Green","year":"2015","journal-title":"Ann Emerg Med"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0485","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00540-014-1845-3","article-title":"Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials","volume":"28","author":"Wang","year":"2014","journal-title":"J Anesth"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0490","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011565","article-title":"Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01)","volume":"6","author":"Rosati","year":"2016","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0495","first-page":"317","article-title":"Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature","volume":"19","author":"Shelton","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.seizure.2018.08.004_bib0500","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.seizure.2014.09.009","article-title":"Treatment of refractory generalized convulsive status epilepticus with enteral topiramate in resource limited settings","volume":"24","author":"Asadi-Pooya","year":"2015","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0505","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11633090-000000000-00000","article-title":"Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study","volume":"26","author":"Hottinger","year":"2012","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0510","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40265-016-0672-2","article-title":"Topiramate in the treatment of generalized convulsive status epilepticus in adults: a systematic review with individual patient data analysis","volume":"77","author":"Brigo","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2018.08.004_bib0515","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.seizure.2016.03.003","article-title":"Assessing the value of topiramate in refractory status epilepticus","volume":"38","author":"Mad\u017ear","year":"2016","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0520","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0525","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/17512433.2016.1156529","article-title":"Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus","volume":"9","author":"Strzelczyk","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Pt. A","key":"10.1016\/j.seizure.2018.08.004_bib0530","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yebeh.2017.03.028","article-title":"Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals","volume":"70","author":"Strzelczyk","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.seizure.2018.08.004_bib0535","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/epi.13787","article-title":"Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus","volume":"58","author":"Niquet","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0540","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/17512433.2015.1091303","article-title":"Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus","volume":"8","author":"Strzelczyk","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0545","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.63","article-title":"Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model","volume":"2","author":"Hanada","year":"2014","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0550","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13760-013-0225-3","article-title":"Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus","volume":"114","author":"R\u00f6sche","year":"2014","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.seizure.2018.08.004_bib0555","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yebeh.2015.04.005","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit","volume":"49","author":"Rohracher","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.08.004_bib0560","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.yebeh.2015.01.036","article-title":"Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus","volume":"45","author":"Redecker","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"8","key":"10.1016\/j.seizure.2018.08.004_bib0565","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40263-013-0078-6","article-title":"Causes of CNS inflammation and potential targets for anticonvulsants","volume":"27","author":"Falip","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2018.08.004_bib0570","article-title":"High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy","author":"Ravizza","year":"2017","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.seizure.2018.08.004_bib0575","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.yebeh.2017.03.033","article-title":"EP2 receptor agonist ONO-AE1-259-01 attenuates pentylenetetrazole- and pilocarpine-induced seizures but causes hippocampal neurotoxicity","volume":"73","author":"Santos","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"Pt. A","key":"10.1016\/j.seizure.2018.08.004_bib0580","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.expneurol.2017.08.009","article-title":"Scavenging reactive oxygen species inhibits status epilepticus-induced neuroinflammation","volume":"298","author":"McElroy","year":"2017","journal-title":"Exp Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0585","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0590","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12974-018-1063-2","article-title":"Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade","volume":"15","author":"DeSena","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.seizure.2018.08.004_bib0595","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000456","article-title":"Intractable epilepsy (IE) and responses to Anakinra, a human recombinant IL-1 receptor agonist (IL-1ra): case reports","author":"Jyonouchi","year":"2016","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0600","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuroscience.2016.04.036","article-title":"Interleukin-1 receptor is a target for adjunctive control of diazepam-refractory status epilepticus in mice","volume":"328","author":"Xu","year":"2016","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0605","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/epi.13688","article-title":"Toll-like receptor 3 deficiency decreases epileptogenesis in a pilocarpine model of SE-induced epilepsy in mice","volume":"58","author":"Gross","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0610","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/epi.13698","article-title":"The effects of C5aR1 on leukocyte infiltration following pilocarpine-induced status epilepticus","volume":"58","author":"Benson","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0615","article-title":"Neuroprotective effects of AEOL10150 in a rat organophosphate model","author":"Liang","year":"2017","journal-title":"Toxicol Sci"},{"issue":"Pt. A","key":"10.1016\/j.seizure.2018.08.004_bib0620","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neuropharm.2016.07.028","article-title":"Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats","volume":"110","author":"Rojas","year":"2016","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.seizure.2018.08.004_bib0625","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0630","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(16)00002-8","article-title":"Cannabidiol for epilepsy: trying to see through the haze","volume":"15","author":"Detyniecki","year":"2016","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2018.08.004_bib0635","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMc1708349","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"377","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0640","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0645","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neulet.2006.09.046","article-title":"Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy","volume":"411","author":"Deshpande","year":"2007","journal-title":"Neurosci Lett"},{"issue":"1-3","key":"10.1016\/j.seizure.2018.08.004_bib0650","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2006.11.030","article-title":"Endocannabinoids block status epilepticus in cultured hippocampal neurons","volume":"558","author":"Deshpande","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0655","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eplepsyres.2015.01.003","article-title":"Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs","volume":"111","author":"Shubina","year":"2015","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0660","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc1512758","article-title":"Cannabinoids in the treatment of epilepsy","volume":"374","author":"Friedman","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0665","article-title":"A spicy status: synthetic cannabinoid (spice) use and new-onset refractory status epilepticus-A case report and review of the literature","author":"Babi","year":"2017","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0670","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.psym.2016.10.006","article-title":"New-onset refractory status epilepticus associated with the use of synthetic cannabinoids","volume":"58","author":"Patel","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.seizure.2018.08.004_bib0675","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.seizure.2016.01.009","article-title":"Cannabidiol oil in the treatment of super refractory status epilepticus. A case report","volume":"35","author":"Rosemergy","year":"2016","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0680","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/epi.13270","article-title":"Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus","volume":"57","author":"Sivakumaran","year":"2016","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0685","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1528-1167.2011.03247.x","article-title":"Positive shifts of the GABAA receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus","volume":"52","author":"Barmashenko","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0690","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuroscience.2015.06.057","article-title":"Enhanced nonsynaptic epileptiform activity in the dentate gyrus after kainate-induced status epilepticus","volume":"303","author":"Nogueira","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.seizure.2018.08.004_bib0695","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2014.10.056","article-title":"Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models","volume":"746","author":"T\u00f6llner","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0700","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.brainresbull.2017.01.022","article-title":"Bumetanide reduce the seizure susceptibility induced by pentylenetetrazol via inhibition of aberrant hippocampal neurogenesis in neonatal rats after hypoxia-ischemia","volume":"130","author":"Hu","year":"2017","journal-title":"Brain Res Bull"},{"issue":"5","key":"10.1016\/j.seizure.2018.08.004_bib0705","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(14)70303-5","article-title":"Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1\/2 trial","volume":"14","author":"Pressler","year":"2015","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0710","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/epi.12480","article-title":"Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential","volume":"55","author":"Shekh-Ahmad","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0715","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2015.04.012","article-title":"The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus","volume":"49","author":"Shekh-Ahmad","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0720","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/epi.12702","article-title":"Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus","volume":"55","author":"Spampanato","year":"2014","journal-title":"Epilepsia"},{"issue":"Suppl. 6","key":"10.1016\/j.seizure.2018.08.004_bib0725","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/epi.12290","article-title":"Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus","volume":"54","author":"Shekh-Ahmad","year":"2013","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0730","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1528-1167.2011.03338.x","article-title":"A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage","volume":"53","author":"White","year":"2012","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2018.08.004_bib0735","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/epi.12838","article-title":"Sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats","volume":"55","author":"Bar-Klein","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0740","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2015.07.003","article-title":"Lidocaine for status epilepticus in adults","volume":"31","author":"Zeiler","year":"2015","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0745","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1017\/cjn.2015.278","article-title":"Lidocaine for status epilepticus in pediatrics","volume":"42","author":"Zeiler","year":"2015","journal-title":"Can J Neurol Sci"},{"issue":"10","key":"10.1016\/j.seizure.2018.08.004_bib0750","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1111\/j.1528-1167.2010.02646.x","article-title":"Oral pregabalin as an add-on treatment for status epilepticus","volume":"51","author":"Novy","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0755","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2015.01.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII)","volume":"111","author":"Bialer","year":"2015","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0760","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12031-017-0968-z","article-title":"Inhibition of P2X7 receptor ameliorates nuclear factor-kappa B mediated neuroinflammation induced by status epilepticus in rat Hippocampus","volume":"63","author":"Huang","year":"2017","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.seizure.2018.08.004_bib0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2017.04.016","article-title":"Glibenclamide ameliorates cerebral edema and improves outcomes in a rat model of status epilepticus","volume":"121","author":"Lin","year":"2017","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.seizure.2018.08.004_bib0770","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/epi.13578","article-title":"2-Deoxy-d-glucose enhances tonic inhibition through the neurosteroid-mediated activation of extrasynaptic GABAA receptors","volume":"57","author":"Forte","year":"2016","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0775","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5214\/ans.0972.7531.200105","article-title":"Reversal of experimentally induced seizure activity in mice by glibenclamide","volume":"20","author":"Pithadia","year":"2013","journal-title":"Ann Neurosci"},{"key":"10.1016\/j.seizure.2018.08.004_bib0780","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnins.2017.00021","article-title":"The ATP-Gated P2X7 receptor As a target for the treatment of drug-resistant epilepsy","volume":"11","author":"Beamer","year":"2017","journal-title":"Front Neurosci"},{"key":"10.1016\/j.seizure.2018.08.004_bib0785","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.yebeh.2015.02.031","article-title":"P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus","volume":"49","author":"Henshall","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0790","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1096\/fj.11-196089","article-title":"Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice","volume":"26","author":"Engel","year":"2012","journal-title":"FASEB J"},{"issue":"11","key":"10.1016\/j.seizure.2018.08.004_bib0795","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112269","article-title":"Hungry neurons: metabolic insights on seizure dynamics","volume":"18","author":"Bazzigaluppi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0800","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1152\/jn.00100.2017","article-title":"Glycolytic inhibition by 2-deoxy-d-glucose abolishes both neuronal and network bursts in an in vitro seizure model","volume":"118","author":"Shao","year":"2017","journal-title":"J Neurophysiol"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0805","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2017.4382","article-title":"Association of time to treatment with short-term outcomes for pediatric patients with refractory convulsive status epilepticus","volume":"75","author":"Ga\u00ednza-Lein","year":"2018","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.seizure.2018.08.004_bib0810","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group","volume":"339","author":"Treiman","year":"1998","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.seizure.2018.08.004_bib0815","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.410380609","article-title":"Experimental status epilepticus alters gamma-aminobutyric acid type A receptor function in CA1 pyramidal neurons","volume":"38","author":"Kapur","year":"1995","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2018.08.004_bib0820","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1528-1157.2003.62402.x","article-title":"Diazepam terminates brief but not prolonged seizures in young, na\u00efve rats","volume":"44","author":"Goodkin","year":"2003","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0825","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0920-1211(02)00085-2","article-title":"Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus","volume":"50","author":"Jones","year":"2002","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0830","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0887-8994(95)00044-G","article-title":"Effect of prehospital treatment on the outcome of status epilepticus in children","volume":"12","author":"Alldredge","year":"1995","journal-title":"Pediatr Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2018.08.004_bib0835","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/01.wnl.0000180959.31355.92","article-title":"Treatment delay and the risk of prolonged status epilepticus","volume":"65","author":"Eriksson","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0840","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ana.25213","article-title":"Status epilepticus: role for etiology in determining response to benzodiazepines","volume":"83","author":"Joshi","year":"2018","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0845","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNP.0000000000000217","article-title":"Monotherapy or Polytherapy for First-Line Treatment of SE?","volume":"33","author":"Alvarez","year":"2016","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.seizure.2018.08.004_bib0850","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2015.02.027","article-title":"Single versus combinatorial therapies in status epilepticus: novel data from preclinical models","volume":"49","author":"L\u00f6scher","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0855","doi-asserted-by":"crossref","first-page":"18284","DOI":"10.3390\/ijms140918284","article-title":"Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions","volume":"14","author":"Reddy","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"1-2","key":"10.1016\/j.seizure.2018.08.004_bib0860","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0006-8993(98)00606-4","article-title":"Self-sustaining status epilepticus after brief electrical stimulation of the perforant path","volume":"801","author":"Mazarati","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.seizure.2018.08.004_bib0865","first-page":"123","article-title":"Rational polytherapy in the treatment of status epilepticus","volume":"11","author":"Walton","year":"1996","journal-title":"Epilepsy Res Suppl"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0870","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/jnc.12787","article-title":"Dynamics of hippocampal acetylcholine release during lithium-pilocarpine-induced status epilepticus in rats","volume":"131","author":"Hillert","year":"2014","journal-title":"J Neurochem"},{"issue":"9","key":"10.1016\/j.seizure.2018.08.004_bib0875","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/epi.13480","article-title":"Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits","volume":"57","author":"Niquet","year":"2016","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0880","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1528-1167.2007.01384.x","article-title":"A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation","volume":"49","author":"Martin","year":"2008","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2018.08.004_bib0885","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1111\/epi.13695","article-title":"Treatment of experimental status epilepticus with synergistic drug combinations","volume":"58","author":"Niquet","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.08.004_bib0890","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2017.04.019","article-title":"Simultaneous triple therapy for the treatment of status epilepticus","volume":"104","author":"Niquet","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"Suppl. 8","key":"10.1016\/j.seizure.2018.08.004_bib0895","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1528-1167.2011.03243.x","article-title":"Rational polytherapy in the treatment of acute seizures and status epilepticus","volume":"52","author":"Wasterlain","year":"2011","journal-title":"Epilepsia"},{"issue":"2-3","key":"10.1016\/j.seizure.2018.08.004_bib0900","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.eplepsyres.2004.02.002","article-title":"Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus","volume":"58","author":"Mazarati","year":"2004","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.seizure.2018.08.004_bib0905","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1528-1167.2008.01713.x","article-title":"Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam","volume":"50","author":"Kaminski","year":"2009","journal-title":"Epilepsia"},{"issue":"1-2","key":"10.1016\/j.seizure.2018.08.004_bib0910","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.brainres.2005.06.013","article-title":"Efficacy of the ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus","volume":"1051","author":"Dorandeu","year":"2005","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.seizure.2018.08.004_bib0915","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejpn.2009.02.004","article-title":"Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial","volume":"14","author":"Sreenath","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"issue":"10","key":"10.1016\/j.seizure.2018.08.004_bib0920","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/j.1528-1167.2010.02688.x","article-title":"Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice","volume":"51","author":"Aranda","year":"2010","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2018.08.004_bib0925","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1474-4422(15)00296-3","article-title":"Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial","volume":"15","author":"Navarro","year":"2016","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.seizure.2018.08.004_bib0930","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/PCC.0000000000000900","article-title":"Refractory status epilepticus in children: intention to treat with continuous infusions of midazolam and pentobarbital","volume":"17","author":"Tasker","year":"2016","journal-title":"Pediatr Crit Care Med"},{"issue":"Pt. A","key":"10.1016\/j.seizure.2018.08.004_bib0935","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.yebeh.2015.07.040","article-title":"Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus","volume":"52","author":"Sabharwal","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.08.004_bib0940","unstructured":"ClinicalTrials.gov. NIH, US National Library of Medicine. Identifier NCT00830531. Pilot study of bumetanide for newborn seizures. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00830531."}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118304485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118304485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:54:28Z","timestamp":1761011668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131118304485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":188,"alternative-id":["S1059131118304485"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2018.08.004","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel drugs and early polypharmacotherapy in status epilepticus","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}